Prothena Announces Appointment of Sanjiv Patel, MBBS, to its Board of Directors
20 mai 2021 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, May 20, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of investigational therapeutics built on protein...
Prothena Reports First Quarter 2021 Financial Results and Provides Updated Financial Guidance and R&D Update
11 mai 2021 16h05 HE
|
Prothena Corporation plc
Net cash used in operating and investing activities was $33.7 million in the first quarter; quarter-end cash and restricted cash position of $345.7 million provides funding to advance the R&D...
Prothena Announces Achievement of $60 Million Milestone From Roche for First Patient Dosed in Phase 2b Study of Prasinezumab in Early Parkinson’s Disease
10 mai 2021 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, May 10, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein...
Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
07 mai 2021 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, May 07, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein...
Prothena to Report First Quarter 2021 Financial Results on May 11th
04 mai 2021 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, May 04, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational...
Prothena Presents Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021
18 avr. 2021 15h05 HE
|
Prothena Corporation plc
Slowing of neuropathy progression for all 7 evaluable patients, evidenced by a +1.29 point mean change in NIS, was more favorable than expected progression of +9.2 pointsImprovement in neuropathy for...
Prothena Announces PRX004 Phase 1 Study Results Selected for Emerging Science Oral Presentation at AAN 2021
15 avr. 2021 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, April 15, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational...
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 avr. 2021 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, April 07, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational...
Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer
05 avr. 2021 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, April 05, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational...
Prothena Announces Pricing of Public Offering of 3,500,000 Ordinary Shares
24 mars 2021 08h00 HE
|
Prothena Corporation plc
DUBLIN, Ireland, March 24, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational...